U.S. Anatomic Pathology Market Share To Reach Scalable Heights Of Growth
U.S. Anatomic Pathology Market Summary
The U.S. anatomic pathology market size was estimated at USD 9.71 billion in 2024 and is projected to reach USD 15.35 billion by 2030, growing at a compound annual growth rate (CAGR) of 7.1% from 2025 to 2030. This market is witnessing strong growth, fueled by rapid advancements in technology and increasing clinical requirements. Anatomic pathology plays a pivotal role in diagnosing and managing a wide range of diseases, particularly cancer, by studying tissue architecture, structure, and cellular anomalies. The market’s growth trajectory is closely linked to the expansion of precision medicine and the increasing need for timely and accurate diagnoses.
A major driver of this market is the incorporation of automation and digital solutions throughout the pathology workflow, including pre-analytical, analytical, and post-analytical phases. The integration of advanced systems, such as gross imaging systems for capturing macroscopic images, digital microscopes for high-resolution image analysis, and automated staining platforms for consistent tissue staining, is significantly transforming traditional pathology practices. These innovations are improving diagnostic precision, operational efficiency, and overall patient care outcomes.
Key Market Trends & Insights
- The consumables segment represented the largest share of the market in 2024, accounting for 68.9%. This dominance can be attributed to the rising demand for reagents, kits, fixatives, dyes, and other pathology-related supplies. With the growing implementation of next-generation sequencing (NGS) and molecular pathology methods, laboratories now require high-quality consumables to ensure reliable results. Additionally, the increasing volume of tissue sample analyses in clinical settings has further driven the need for continuous supply and replenishment of consumables.
- In 2024, the disease diagnosis segment held the largest market share, driven by the increasing burden of chronic conditions such as cancer, infectious diseases, and autoimmune disorders. As the incidence of these diseases continues to rise, healthcare providers are seeking more advanced, efficient, and accurate diagnostic solutions to ensure early detection and effective treatment planning. The ability of anatomic pathology to offer highly specific insights into disease mechanisms makes it indispensable in modern diagnostic workflows.
- The hospital segment captured the largest market share in 2024 due to several key factors. These include the high rate of hospital admissions for cancer treatment, frequent readmissions related to chronic disease management, and the presence of specialized pathology laboratories within hospitals. Hospital-based labs benefit from access to sophisticated diagnostic instruments and a skilled workforce, which enhances their ability to conduct comprehensive anatomic pathology analyses with higher throughput and diagnostic reliability.
- The diagnostic laboratories segment is projected to witness the fastest growth over the forecast period. The increasing prevalence of non-communicable diseases in the U.S., including cardiovascular and respiratory conditions, is driving demand for dedicated diagnostic testing outside hospital environments. Concurrently, diagnostic laboratories are adopting digital pathology platforms, artificial intelligence-based interpretation tools, and integrated information systems, which collectively boost their operational efficiency, reduce turnaround times, and expand their diagnostic capabilities. This technological evolution is making diagnostic labs an increasingly preferred setting for pathology services.
Order a free sample PDF of the U.S. Anatomic Pathology Market Intelligence Study, published by Grand View Research.
Market Size & Forecast
- 2024 Market Size: USD 9.71 billion
- 2030 Projected Market Size: USD 15.34 billion
- CAGR (2025 - 2030): 7.1%
Key Companies & Market Share Insights
Leading companies operating in the U.S. anatomic pathology industry include Danaher, Quest Diagnostics Incorporated, Laboratory Corporation of America Holdings (Labcorp), Agilent Technologies, Inc., and Cardinal Health. These organizations are playing a key role in shaping the industry landscape through technological innovation, strategic acquisitions, and the expansion of diagnostic service offerings across the healthcare ecosystem.
Danaher Corporation operates as a globally diversified science and technology enterprise, with a strong focus on diagnostics, life sciences, biotechnology, and environmental technologies. The company delivers a wide portfolio of instruments and consumables to support efficient and precise pathology workflows. Labcorp, another industry leader, offers comprehensive diagnostic and laboratory services. Its anatomic pathology portfolio includes sophisticated histology, cytology, and molecular pathology tools that enable healthcare providers to offer accurate diagnoses and individualized care plans, especially in oncology.
Key Players
- Danaher Corporation
- Quest Diagnostics Incorporated
- Labcorp
- Agilent Technologies, Inc.
- Cardinal Health
- Sakura Finetek USA, Inc.
- NeoGenomics Laboratories, Inc.
- BioGenex
- Bio SB
Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.
Conclusion
The U.S. anatomic pathology market is poised for substantial growth, propelled by rising chronic disease incidence, technological innovation, and growing demand for accurate diagnostic solutions. Increasing integration of automation and digital pathology across healthcare facilities is enhancing diagnostic accuracy and efficiency. The dominance of consumables and hospital-based pathology underscores the market’s reliance on established infrastructures, while diagnostic laboratories are gaining traction through rapid adoption of digital technologies. Key industry players continue to expand offerings and innovate, supporting the market’s evolution. As precision medicine advances, anatomic pathology will remain an essential pillar of disease diagnosis and patient-centered treatment strategies in the U.S.
Comments
Post a Comment